Dalbavancin Interactions: Alcohol, Caffeine, Food & Other Compounds

Dalbavancin is a semisynthetic lipoglycopeptide antibiotic given intravenously, developed from the teicoplanin A4 scaffold and characterised by an unusually long terminal half-life that permits weekly or single-dose administration schedules, as described in a 2008 pharmacy review (PMID 18359966). Because it is an infusion-administered agent rather than an oral one, many of the interaction questions asked about oral antibiotics, timing relative to meals, fasting windows, beverages taken alongside a tablet, do not map onto it in the way readers may expect. This page summarises what the verified literature reports about dalbavancin's disposition and co-administration, and states plainly where no interaction study exists.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical or treatment question. Nothing here is a verdict that any combination is safe, unsafe, advisable or inadvisable.

Why Dalbavancin's Pharmacokinetics Shape the Interaction Question

Interaction potential for most drugs is driven by shared metabolic enzymes, shared transporters, competition for plasma protein binding, or altered absorption. A 2022 clinical pharmacokinetics and pharmacodynamics review reported that dalbavancin exhibits very high plasma protein binding (predominantly to albumin), a long terminal half-life supporting once-weekly and single-dose regimens, and elimination that is not dependent on cytochrome P450 metabolism (PMID 34931283). A separate pharmacokinetic/pharmacodynamic analysis published in 2017 likewise described dalbavancin's concentration profile and the prolonged exposure that follows intravenous administration (PMID 28129817).

The 2008 review characterised dalbavancin as a lipoglycopeptide that inhibits cell wall synthesis in Gram-positive organisms and that is administered intravenously rather than orally (PMID 18359966). A 2022 review of long-acting lipoglycopeptides similarly positioned dalbavancin and oritavancin as agents whose extended half-lives reduce the number of administrations required for Gram-positive infections (PMID 35475634). Researchers use these disposition properties, intravenous route, minimal hepatic metabolism, high protein binding, as the starting point when reasoning about whether a given co-exposure could plausibly change dalbavancin concentrations. That reasoning is mechanistic inference, not an interaction study result.

Dalbavancin and Alcohol: What the Literature Reports

No dedicated trial examining dalbavancin administered with ethanol appears among the verified papers summarised on this page. None of the pharmacokinetic reviews cited here reported an alcohol-interaction study, an ethanol challenge arm, or a disulfiram-like reaction endpoint for dalbavancin (PMID 34931283). The absence of a study is itself the finding: readers encountering claims about dalbavancin and alcohol should note that the verified literature here does not contain a trial addressing that pairing.

The mechanistic reasoning researchers apply (labelled as reasoning, not evidence)

Two mechanisms are usually invoked when alcohol is discussed alongside antibiotics. The first is a disulfiram-like reaction, which arises when a drug inhibits aldehyde dehydrogenase; this has historically been linked to certain agents containing particular side-chain structures, and dalbavancin's lipoglycopeptide structure described in the 2008 review is not of that class (PMID 18359966). The second is competition for hepatic metabolism, which is the usual pathway by which ethanol alters drug exposure; the 2022 pharmacokinetic review reported that dalbavancin is not substantially metabolised by cytochrome P450 enzymes (PMID 34931283). On that basis researchers would not predict a metabolic interaction, but prediction is not measurement, and no study in this citation set tested it.

A separate consideration raised in the clinical literature is the population in which dalbavancin is frequently studied. A 2022 report on dalbavancin use during the COVID-19 pandemic described its deployment to reduce hospital length of stay and outpatient infusion visits for Gram-positive infections (PMID 36265122), and a 2025 two-centre Greek retrospective study of bone and joint infections reported real-world outcomes in patients receiving dalbavancin outside controlled trial conditions (PMID 41305347). Observational series of this kind describe treatment courses and outcomes; they did not isolate alcohol exposure as a variable.

Dalbavancin and Caffeine: What the Literature Reports

No caffeine-interaction study of dalbavancin appears in the verified papers covered here. Caffeine is cleared predominantly by CYP1A2, and the 2022 pharmacokinetic review reported that dalbavancin's elimination does not proceed through cytochrome P450-mediated metabolism (PMID 34931283). Researchers therefore treat a shared-enzyme interaction between the two as mechanistically implausible, again, inference drawn from disposition data rather than a measured result. The 2017 pharmacokinetic/pharmacodynamic paper described dalbavancin's exposure parameters without reporting any caffeine co-administration arm (PMID 28129817).

Food, Fasting and Infusion Context

Food-effect studies are conducted for orally absorbed drugs, because gastric contents can change dissolution, transit and first-pass exposure. Dalbavancin was described in the 2008 review as an intravenously administered lipoglycopeptide (PMID 18359966), and the 2022 review of long-acting lipoglycopeptides likewise framed dalbavancin as a parenteral agent whose long half-life defines its administration schedule (PMID 35475634). Because the drug bypasses the gastrointestinal tract entirely, gastrointestinal absorption variables of the kind tested in food-effect studies do not apply to its systemic exposure. No fasted-versus-fed pharmacokinetic comparison for dalbavancin appears in the verified set (PMID 34931283).

Other Compounds: What Studies Examined

Co-administration with other antimicrobials

Most published co-administration data for dalbavancin come from combination-therapy contexts rather than from formal drug-drug interaction pharmacokinetic studies. A 2023 review of Enterococcus faecalis infective endocarditis discussed treatment approaches for this organism, including the role of newer agents in difficult-to-treat enterococcal disease (PMID 37107066). A 2021 paper on therapeutic options for vanB genotype vancomycin-resistant enterococci examined which agents retain activity against that resistance genotype (PMID 32799629). A 2020 review of resistant staphylococcal infections surveyed the agents available for methicillin-resistant and other difficult staphylococci (PMID 32148777). These papers described antimicrobial activity and treatment strategy; they did not report that dalbavancin altered the plasma pharmacokinetics of a co-administered drug.

Device and implant settings

A 2006 review of infections associated with orthopaedic implants discussed the challenges of treating biofilm-associated infection on prosthetic material (PMID 16804382), and the 2025 Greek retrospective study reported real-world dalbavancin use in bone and joint infections across two centres (PMID 41305347). These are clinical-context papers; neither was designed as an interaction study.

Immune-cell effects observed in vitro

A 2023 laboratory study reported that glycopeptide antibiotics impaired neutrophil effector functions in experimental systems (PMID 37321197). That is a pharmacodynamic observation at the cellular level rather than a pharmacokinetic drug-drug interaction, and the study did not test combinations with alcohol, caffeine or dietary compounds.

Interaction Questions Mapped to the Evidence

Adverse Events and Tolerability: What Studies Report

Interaction questions are often really tolerability questions, so it is worth separating the two. The 2008 pharmacy review described dalbavancin's clinical profile and place in therapy among antistaphylococcal agents (PMID 18359966), and a 2005 paper on newer antistaphylococcal agents reviewed the then-emerging agents in this class (PMID 15659968). The 2025 Greek retrospective study of bone and joint infections reported real-world experience with dalbavancin across two centres (PMID 41305347), and the 2022 pandemic-context report described its use to reduce infusion-centre and inpatient exposure (PMID 36265122). None of these reports attributed an adverse event to a specific interaction with alcohol, caffeine or food. The study findings summarised here describe treatment courses and outcomes, not co-exposure experiments.

How to Read Absence of Evidence

When no interaction study exists, three statements can be made honestly, and a fourth cannot:

1. The verified literature summarised here contains no trial of that combination (PMID 34931283).
2. Disposition data can make an interaction mechanistically more or less plausible, for dalbavancin, non-CYP elimination and parenteral administration were the reported features (PMID 34931283, PMID 18359966).
3. Mechanistic plausibility is reasoning, not a measured outcome (PMID 28129817).
4. What cannot be said is that a combination is safe or unsafe, that is a clinical judgement for a prescribing physician, not a conclusion this page draws.

Readers wanting the broader pharmacology, mechanism and clinical-study background for this agent can continue to the dalbavancin overview in the PeptideU learn library.

References

• Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin (Clinical Pharmacokinetics, 2022)
• [Dalbavancin: pharmacokinetic and pharmacodynamic parameters] (Enfermedades Infecciosas y Microbiologia Clinica, 2017)
• Dalbavancin: a new lipoglycopeptide antibiotic (American Journal of Health-System Pharmacy, 2008)
• New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides (Antimicrobial Agents and Chemotherapy, 2022)
• Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge (Antibiotics, 2023)
• Therapeutic Options for Infections due to vanB Genotype Vancomycin-Resistant Enterococci (Microbial Drug Resistance, 2021)
• The treatment of resistant staphylococcal infections (F1000Research, 2020)
• Dalbavancin During the COVID-19 Pandemic (Surgical Technology International, 2022)
• Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study (Pathogens, 2025)
• Infections associated with orthopedic implants (Current Opinion in Infectious Diseases, 2006)
• Glycopeptide Antibiotics Impair Neutrophil Effector Functions (International Archives of Allergy and Immunology, 2023)
• Newer antistaphylococcal agents (Current Opinion in Pediatrics, 2005)